Amlan® International to Present Innovative Mineral Technology Solutions at VIV Asia 2023
- Annually one-third of the world’s broiler meat is supplied by Asia, making this region critical to the global food supply.
- VIV Asia attendees can meet with Amlan technical experts and the local sales team to learn more about their innovative mineral-based products at booth 3650.
- Amlan will host two presentations on natural alternatives to promote animal health and improve production efficiencies at the VIV Asia 2023 global trade show.
- Dr. Aldo Rossi will present features of recently launched Phylox® (available in select international markets), a natural alternative to anticoccidial drugs that improves gut health and production efficiencies.
- Dr. Marc Herpfer will present Calibrin®-Z (available in select international markets) research and discuss the capabilities of advanced mineral technology for biotoxin control.
CHICAGO, March 01, 2023 (GLOBE NEWSWIRE) -- Amlan® International, the animal health business of Oil-Dri® Corporation of America and a global leader in natural, mineral-based feed additives for poultry and livestock, will provide producers in the Asia-Pacific region with an opportunity to learn about research-backed solutions that optimize gut health and improve economic production at the upcoming VIV Asia 2023 conference to be held at the IMPACT venue, March 8-10, 2023, in Bangkok, Thailand. The conference, which features more than 200 professional speakers and more than 45,000 visitors, offers an opportunity for producers and companies like Amlan to connect at the largest feed-to-food global trade show in Asia.
Asia supplied 36% of the world’s demand for broiler meat, producing 44 million metric tons in 2020. Poultry producers in India, Indonesia and Japan are leading broiler meat production in the Asian region, with Vietnam and Pakistan showing rapid growth in the last five years.
Additionally, almost one-half of annual global swine production and over 30% of the world’s milk production is from Asia.
Recognizing Asia's impact on the global food supply, Amlan has built a robust sales and technical service team throughout the region. During the conference, producers can visit Amlan experts at booth 3650 where they will showcase their full range of feed additives, including Phylox®, Calibrin®-Z and Varium® (all available in select international markets), which promote optimal intestinal health and feed efficiency, adding value for producers by maximizing poultry and livestock performance.
“Our mineral-based products protect poultry and livestock health by binding bacterial toxins and mycotoxins. We are excited to be presenting to this vital international audience,” said Dr. Saksake Pacharadit, Regional Sales Manager for the Asia-Pacific Region. “Unlike other clay-based products, Amlan selects our single-source mineral and leverages a proprietary thermal processing technique (not harsh chemicals), tailored specifically for each of our products, to optimize product efficacy. We’re pleased to be showcasing our products in such an important market like Thailand where the production of broiler and pork meat ranks among the top five for the Asia-Pacific region.”
Amlan will also host two informative presentations during VIV Asia. The first, to be held at 11 a.m. on Wednesday, March 8, will be presented by Dr. Marc Herpfer, Vice President of New Technologies, Oil-Dri® Corporation of America, who will discuss “Natural Mineral Technology for Advanced Biotoxin Control.” At 11 a.m. on Thursday, March 9, Dr. Aldo Rossi, Vice President, Innovation and Technical Service, Amlan International, will present on “Natural Alternatives for Controlling Coccidiosis.”
“During VIV Asia, attendees will get acquainted with Amlan’s innovative and intelligent feed additive solutions through two presentations by Amlan experts,” said Dr. Wade Robey, Vice President of Agriculture, Oil-Dri Corporation of America, and President, Amlan International. “Coccidiosis and performance challenges affect poultry production costing the global chicken industry billions every year. Our products, Calibrin-Z and Phylox, support gut health, improve productivity, and help drive producers' profits.”
For more information about Phylox, Calibrin-Z, Varium or Amlan’s full portfolio of products, visit www.amlan.com.
Company Information
Amlan is the animal health business of Oil-Dri Corporation of America, a leading global manufacturer and marketer of sorbent minerals. Oil-Dri leverages over 80 years of expertise in mineral science to selectively mine and process their unique mineral for consumer and business-to-business markets. Oil-Dri Corporation of America doing business as “Amlan International” is a publicly traded stock on the New York Stock Exchange (NYSE: ODC). Amlan International sells feed additives across the world. Product availability may vary by country, associated claims do not constitute medical claims and may differ based on government requirements.
Reagan Culbertson
Media Contact
press@amlan.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8dc742dc-e446-459b-9280-bec32c356e77
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Grant of Restricted Stock Units and Warrants to Employees in Genmab8.6.2023 23:22:17 CEST | Press release
Company Announcement COPENHAGEN, Denmark; June 8, 2023 –Genmab A/S (Nasdaq:GMAB) announced todaythat the Board decided to grant 7,825 restricted stock units and 8,106 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 2,688. The restricted stock units will vest on the first banking day of the month following a period of three years from the date of grant. Furthermore, the restricted stock units are subject to vesting conditions set out in the restricted stock unit program adopted by the Board of Directors. Information concerning Genmab’s restricted stock unit program can be found on www.genmab.com under Investors > Governance > Compensation > Restricted Stock Units. The exercise price fo
Press Release: FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants8.6.2023 23:19:00 CEST | Press release
FDA Advisory Committee unanimously recommendsnirsevimab as first immunization against RSV disease forall infants Nirsevimab would be the first immunization specifically designed to protect all infants through their first RSV season, if approvedAcross all clinical trials, a single dose of nirsevimab delivered high, consistent and sustained efficacy and favorable safety against RSV diseaseThe FDA has indicated it will work to expedite its review; Sanofi remains committed to delivering nirsevimab in time for the 2023-2024 RSV season Paris, June 8, 2023. The U.S. Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously 21 to 0 that Sanofi and AstraZeneca’s nirsevimab has a favorable benefit risk profile for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season. The Committee also voted 19 to 2 in support of nirsevimab’s favorable benefit ris
DBV Technologies to Participate in Upcoming EAACI Congress 20238.6.2023 22:30:00 CEST | Press release
Montrouge, France, June 8, 2023 DBV Technologies to Participate in Upcoming EAACI Congress 2023 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 9 – 11, 2023, in Hamburg, Germany. DBV will present three posters and will also host a symposium and exhibit booth in the EAACI exhibit hall. Data to be presented during the scientific sessions will describe the current burden of peanut allergy and treatment management strategies for children in the U.K. DBV will also present data from its completed EPITOPE Phase 3 study assessing the efficacy and safety of epicutaneous immunotherapy (EPIT) using Viaskin Peanut™ in toddlers aged 1-3 years with or without concomitant asthma. The toddler age-group represents the age range in which many peanut-allergic children are diagnosed, yet there are currently n
GOGL - Transactions made under the buy-back program8.6.2023 22:30:00 CEST | Press release
Reference is made to the stock announcement on October 4, 2022, where Golden Ocean Group Limited (OSE/NASDAQ: GOGL) announced the commencement of its share buy-back program of maximum USD 100 million to purchase up to an aggregate of 10,000,000 of the company's common shares in a 12-month period from the announcement. Golden Ocean Group Limited (“GOGL” or the “Company”) announces that the Company has during the week ending Friday June 2, 2023, purchased 25,343 of the Company’s own common stocks. 343 of the shares have been bought on the Oslo Stock Exchange at an average price of NOK 80.00 per share and 25,000 of the shares have been bought on Nasdaq at an average price of USD 7.19 per share. Following the completion of the above transactions, GOGL owns a total of 952,428 of own shares, corresponding to 0.47% of the Company’s share capital. An overview of all transactions made under the buy-back program that have been carried out during the above-mentioned date is attached to this repor
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants8.6.2023 22:00:00 CEST | Press release
Company announcement – No. 25 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, June 8, 2023– Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 36,006 divided into 36,006 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under several of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pharma’s incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand Pharma share at a prespecified price, the exercise price, in specific predefined time periods before expiration. For a more detailed description of Zealand Pharma’s warrant programs, see the company’s Articles of Association, which are